[go: up one dir, main page]

MX2011000255A - Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer. - Google Patents

Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.

Info

Publication number
MX2011000255A
MX2011000255A MX2011000255A MX2011000255A MX2011000255A MX 2011000255 A MX2011000255 A MX 2011000255A MX 2011000255 A MX2011000255 A MX 2011000255A MX 2011000255 A MX2011000255 A MX 2011000255A MX 2011000255 A MX2011000255 A MX 2011000255A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination
aminoheteroaryl compound
met antagonist
Prior art date
Application number
MX2011000255A
Other languages
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2011000255A publication Critical patent/MX2011000255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención también se refiere a una composición que comprende un anticuerpo antagonista a c-Met, y un compuesto aminoheteroarilo, particularmente como un medicamento. La presente invención también comprende una composición farmacéutica que comprende el anticuerpo anti c-Met y el compuesto aminoheteroarilo como productos de combinación para uso simultáneo separado o secuencial. La invención se refiere al uso de la composición de la invención para el tratamiento de cáncer en un mamífero.
MX2011000255A 2008-07-08 2009-07-08 Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer. MX2011000255A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12959808P 2008-07-08 2008-07-08
EP20080305387 EP2143441A1 (en) 2008-07-08 2008-07-08 Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PCT/EP2009/058709 WO2010003992A1 (en) 2008-07-08 2009-07-08 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2011000255A true MX2011000255A (es) 2014-04-16

Family

ID=39924962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011000255A MX2011000255A (es) 2008-07-08 2009-07-08 Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.

Country Status (15)

Country Link
US (3) US8623359B2 (es)
EP (2) EP2143441A1 (es)
JP (1) JP5677949B2 (es)
KR (1) KR20110043548A (es)
CN (1) CN102083465B (es)
AU (1) AU2009268040B2 (es)
BR (1) BRPI0915446A2 (es)
CA (1) CA2730110C (es)
ES (1) ES2668970T3 (es)
GE (1) GEP20135829B (es)
IL (1) IL210404A (es)
MA (1) MA32458B1 (es)
MX (1) MX2011000255A (es)
RU (1) RU2526171C2 (es)
WO (1) WO2010003992A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
WO2012003338A1 (en) * 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
KR20140045440A (ko) * 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
KR102306656B1 (ko) * 2013-07-03 2021-09-29 삼성전자주식회사 항 c-Met 항체를 이용하는 암의 병용 치료
EP3033434A2 (en) * 2013-08-14 2016-06-22 Qiagen Mansfield, Inc. Compositions and methods for multimodal analysis of cmet nucleic acids
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR741285A (es) 1932-08-22 1933-02-08
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ES2344793T3 (es) * 2004-08-05 2010-09-07 Genentech, Inc. Antagonistas anti-cmet humanizados.
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
KR101026676B1 (ko) * 2005-12-05 2011-04-04 화이자 프로덕츠 인코포레이티드 비정상 세포 성장의 치료 방법
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
JP5857060B2 (ja) * 2010-11-03 2016-02-10 アルゲン−エックス エヌ．ブイ． 抗ｃ−Ｍｅｔ抗体

Also Published As

Publication number Publication date
AU2009268040B2 (en) 2014-11-20
EP2143441A1 (en) 2010-01-13
BRPI0915446A2 (pt) 2015-11-10
ES2668970T3 (es) 2018-05-23
AU2009268040A1 (en) 2010-01-14
WO2010003992A1 (en) 2010-01-14
CA2730110A1 (en) 2010-01-14
US20140186356A1 (en) 2014-07-03
MA32458B1 (fr) 2011-07-03
GEP20135829B (en) 2013-05-27
KR20110043548A (ko) 2011-04-27
RU2526171C2 (ru) 2014-08-20
RU2011103125A (ru) 2012-08-20
IL210404A0 (en) 2011-03-31
WO2010003992A8 (en) 2011-02-10
CN102083465A (zh) 2011-06-01
JP2011527313A (ja) 2011-10-27
US9011865B2 (en) 2015-04-21
IL210404A (en) 2017-06-29
US20150250780A1 (en) 2015-09-10
CN102083465B (zh) 2015-05-27
US9375425B2 (en) 2016-06-28
EP2315601A1 (en) 2011-05-04
CA2730110C (en) 2018-10-02
EP2315601B1 (en) 2018-02-14
US20110117098A1 (en) 2011-05-19
JP5677949B2 (ja) 2015-02-25
US8623359B2 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
MY160456A (en) Benzodiazepine bromodomain inhibitor
WO2009129246A3 (en) Compositions and methods for preparing and using same
PH12013502192A1 (en) Antibodies against human angiopoietin 2
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EP2214770A4 (en) METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
GB201118656D0 (en) New compounds
MX2012005507A (es) Antagonistas de espiro-oxindol de mdm2.
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
TN2009000213A1 (en) Combination
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal